New Vaccine Agreements for COVAX

New Vaccine Agreements for COVAX
share Share

COVAX, the global initiative to ensure equitable access to COVID-19 vaccines across the world, has announced new agreements for Pfizer/BioNTech and AstraZeneca/Oxford vaccines delivery, about 200 million doses in total.

 

You might also like: COVID-19 Vaccines: Tracking and Future Distribution

 

Specifically, COVAX reached an advance purchase agreement with Pfizer to receive up to 40 million doses of the Pfizer-BioNTech vaccine candidate. The vaccine has already been approved by the World Health Organization (WHO) for emergency use. The parties will now negotiate the conditions for delivery.

 

Another confirmed deal involves receiving the first 100 million doses of the AstraZeneca/Oxford vaccine manufactured by Serum Institute of India, in line with the existing agreement with the latter. WHO Emergency Use Listing is pending for the vaccine, but once the authorisation is granted (the decision is expected by mid-February), the majority of these is to be delivered in the first quarter 2021. Earlier the vaccine was approved for restricted emergency use by the Drugs Controller General of India.

 

A parallel agreement with AstraZeneca sees the delivery of another 50 million doses of the vaccine to COVAX participants, also in the first quarter. Similarly, by mid-February WHO should have decided whether to approve the COVAX-specific manufacturing network for this batch.

 

Gavi, the Vaccine Alliance, which leads COVAX procurement and delivery, is providing about €123 million ($150 million) to fund these deals.

 

WHO is also preparing to launch a ‘Country Readiness Portal’ later this month. The participating countries will be able to submit final national deployment and vaccination plans (NDVPs) through the portal, which is a necessary step for planning the vaccine allocation. In turn, by the end of January COVAX should provide indicative plans for vaccine delivery to its 190 participating countries.

 

Overall, COVAX has already secured access to over 2 billion doses of several vaccine candidates, and it is hoped that by the end of the year 92 lower-income economies will receive at least 1.3 billion doses, with the aim is to inoculate at least 20% of the population in each participating country.

 

Source: WHO

Image credit: MONTAE via iStock

«« Investigation of EU COVID-19 Vaccine Contracts


Close Circle Affects Behaviour During Pandemic »»

Published on : Sat, 23 Jan 2021



Related Articles
Investigation of EU COVID-19 Vaccine Contracts

The European Ombudsman is investigating the European Commission’s refusal to give public access to documents concerning the... Read more

Free WHO Course on Rehabilitation in COVID-19 Patients

The World Health Organization (WHO) has launched another free online course of its Clinical Management of Patients with... Read more

Global Assessment of Health Information Systems: How Do Countries Perform?

The World Health Organization has released its ‘ Global report on health data systems and capacity, 2020 ’ based on the... Read more

AstraZeneca, World Health Organization (WHO), Pfizer/BioNTech, COVID-19 vaccination, COVAX, Gavi New Vaccine Agreements for COVAX

No comment


Please login to leave a comment...

Highlighted Products